ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Despite their efficacy in the inhibition of BCR-ABL kinase activity, TKIs appear to be ineffective against a small reservoir of CML stem cells not “oncogene-addicted” [11, 12].